Merck Tbk PT

Merck Tbk PT maintains a conservative capital structure with a debt-to-equity ratio of 0.01 and a current ratio of 4.26, indicating strong short-term liquidity coverage. The company holds total equity of IDR 975.7 billion against total liabilities of IDR 296.5 billion, with long-term debt limited to IDR 14.2 billion. Despite the strong current ratio, the risk assessment flags medium liquidity risk and notes that net cash is negative after subtracting total debt, suggesting potential working capital constraints or significant cash equivalents not fully offsetting debt obligations in specific accounting treatments.

Profitability metrics show a return on equity of 14.66% and a return on assets of 11.24%, reflecting efficient use of capital. The company generated net income of IDR 243.9 billion on revenue of IDR 1.2 trillion, resulting in a net margin of approximately 20.3%. Operating income stands at IDR 320.3 billion, demonstrating a healthy operating margin of roughly 26.7%. Without cohort median data for direct comparison, these returns appear robust for a pharmaceutical entity, supported by strong free cash flow of IDR 184.6 million.

With a debt-to-equity ratio of just 0.01, Merck Tbk carries minimal leverage compared to the 0.32 cohort median.

Revenue contracted 5.4% year-over-year, indicating weakening top-line growth momentum in the most recent fiscal period.